Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Vit Georgia Parmi | Pharma | 14.0% | 48th pct | 110 |
| Med Parmasi Group | Pharma | -0.9% | 14th pct | 110 |
| Pip Company | Pharma | -15.5% | 3rd pct | 110 |
| Medimex | Pharma | — | no FY data | 110 |
| Sando Pharma | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 3 of 5 peers filed FY2024. Switch to FY2018 (5 of 5).
| Line item | Pip Company | Med Parmasi Group | Vit Georgia Parmi | Medimex | Sando Pharma |
|---|---|---|---|---|---|
| Total Revenue | 1,276 | 1,185 | 1,023 | — | — |
| Total COGS | -1,174 | -752 | -641 | — | — |
| Gross Profit | 102 | 433 | 382 | — | — |
| Gross Margin | 8.0% | 36.5% | 37.3% | — | — |
| Total Operating Expenses | -301 | -444 | -239 | — | — |
| EBITDA | -198 | -11 | 143 | — | — |
| EBITDA Margin | -15.5% | -0.9% | 14.0% | — | — |
| Total D&A | -1 | -61 | -12 | — | — |
| EBIT / Operating Income | -199 | -72 | 131 | — | — |
| Total Other Income | -110 | -32 | — | — | — |
| Profit Before Tax | -309 | -105 | 131 | — | — |
| Total Income Tax | 0 | 0 | 0 | — | — |
| Net Profit / (Loss) | -309 | -48 | 131 | — | — |
| Net Margin | -24.2% | -4.1% | 12.8% | — | — |
Not every picked company reports every selected year — FY2024: no filing for Medimex and Sando Pharma. Those cells are left blank (no filing), not zero.